Dong-E-E-Jiao Co.,Ltd.

SZSE:000423 주식 보고서

시가총액: CN¥36.9b

Dong-E-E-JiaoLtd 과거 수익 실적

과거 기준 확인 4/6

Dong-E-E-JiaoLtd has been growing earnings at an average annual rate of 49.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 10.5% per year. Dong-E-E-JiaoLtd's return on equity is 15.3%, and it has net margins of 27.1%.

주요 정보

49.2%

수익 성장률

49.2%

EPS 성장률

Pharmaceuticals 산업 성장10.9%
매출 성장률10.5%
자기자본 수익률15.3%
순이익27.1%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Dong-E-E-JiaoLtd's (SZSE:000423) Performance Is Even Better Than Its Earnings Suggest

Mar 31
Dong-E-E-JiaoLtd's (SZSE:000423) Performance Is Even Better Than Its Earnings Suggest

Recent updates

Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 14
Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) Shares Climb 34% But Its Business Is Yet to Catch Up

Dong-E-E-Jiao Co.,Ltd. (SZSE:000423) Shares Could Be 37% Below Their Intrinsic Value Estimate

Sep 13
Dong-E-E-Jiao Co.,Ltd. (SZSE:000423) Shares Could Be 37% Below Their Intrinsic Value Estimate

Are Dong-E-E-Jiao Co.,Ltd. (SZSE:000423) Investors Paying Above The Intrinsic Value?

May 21
Are Dong-E-E-Jiao Co.,Ltd. (SZSE:000423) Investors Paying Above The Intrinsic Value?

Dong-E-E-JiaoLtd's (SZSE:000423) Performance Is Even Better Than Its Earnings Suggest

Mar 31
Dong-E-E-JiaoLtd's (SZSE:000423) Performance Is Even Better Than Its Earnings Suggest

Analysts Are Updating Their Dong-E-E-Jiao Co.,Ltd. (SZSE:000423) Estimates After Its Annual Results

Mar 25
Analysts Are Updating Their Dong-E-E-Jiao Co.,Ltd. (SZSE:000423) Estimates After Its Annual Results

Some Shareholders Feeling Restless Over Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) P/E Ratio

Mar 21
Some Shareholders Feeling Restless Over Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) P/E Ratio

수익 및 비용 분석

Dong-E-E-JiaoLtd 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

SZSE:000423 수익, 비용 및 수입 (CNY Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 245,6161,5192,263177
30 Jun 245,2961,3582,095183
31 Mar 245,1001,2741,991190
31 Dec 234,7151,1511,839173
30 Sep 234,4241,0511,804130
30 Jun 234,3831,0031,756130
31 Mar 234,2208961,750131
01 Jan 234,0427801,691138
30 Sep 224,0706521,563157
30 Jun 223,9885991,538153
31 Mar 224,0064931,534147
01 Jan 223,8494401,414148
30 Sep 214,1953661,783129
30 Jun 214,0012771,600140
31 Mar 213,7051891,500148
31 Dec 203,409431,399154
30 Sep 202,181-6851,450147
30 Jun 202,175-7321,541164
31 Mar 202,116-9321,617178
31 Dec 192,970-4551,765205
30 Sep 195,7841,0692,018285
30 Jun 196,2431,4162,105277
31 Mar 196,9341,8692,176270
31 Dec 187,3382,0852,198241
30 Sep 187,2762,0232,183233
30 Jun 187,4242,0052,082303
31 Mar 187,3922,0492,081259
31 Dec 177,3722,0442,178226
30 Sep 176,8131,8732,165116
30 Jun 176,5771,9252,1450
31 Mar 176,5101,9132,1430
31 Dec 166,3171,8522,0960
30 Sep 165,6491,7211,7920
30 Jun 165,5771,6821,7760
31 Mar 165,5011,6431,7260
31 Dec 155,4501,6251,6810
30 Sep 155,1901,5721,6000
30 Jun 154,8301,5161,4320
31 Mar 154,4941,4641,3150
31 Dec 144,0091,3661,1100
30 Sep 143,7691,2651,0110
30 Jun 143,9901,2821,1480
31 Mar 143,9951,2471,1350
31 Dec 134,0161,2031,1520

양질의 수익: 000423 has high quality earnings.

이익 마진 증가: 000423's current net profit margins (27.1%) are higher than last year (23.8%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: 000423's earnings have grown significantly by 49.2% per year over the past 5 years.

성장 가속화: 000423's earnings growth over the past year (44.6%) is below its 5-year average (49.2% per year).

수익 대 산업: 000423 earnings growth over the past year (44.6%) exceeded the Pharmaceuticals industry -1.2%.


자기자본 수익률

높은 ROE: 000423's Return on Equity (15.3%) is considered low.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기